- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Valion Bio, Inc.: With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge | 287 | ACCESS Newswire | Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based production... ► Artikel lesen | |
| Mi | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Valion Bio, Inc.: Valion Bio: Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers | 396 | ACCESS Newswire | Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹Medical countermeasures need to scale along... ► Artikel lesen | |
| 05.10. | Valion Bio, Inc.: New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod | 294 | ACCESS Newswire | Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data... ► Artikel lesen | |
| 01.10. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.09. | Valion Bio, Inc.: Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity | 369 | ACCESS Newswire | Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod... ► Artikel lesen | |
| VALION BIO Aktie jetzt für 0€ handeln | |||||
| 23.09. | Führungswechsel bei Valion Bio: Dean Zikria wird Interims-CEO | 3 | Investing.com Deutsch | ||
| 23.09. | Valion Bio, Inc.: Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions | 365 | ACCESS Newswire | Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23... ► Artikel lesen | |
| 23.09. | Valion Bio, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 22.09. | Valion Bio regains Nasdaq minimum bid price compliance | 2 | Investing.com | ||
| 22.09. | Valion Bio erfüllt wieder NASDAQ-Mindestkursanforderung | 4 | Investing.com Deutsch | ||
| 22.09. | Valion Bio, Inc.: Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule | 260 | ACCESS Newswire | Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company) announced... ► Artikel lesen | |
| 01.09. | Valion Bio, Inc.: Valion Bio Announces Changes to Management and Board of Directors | 405 | ACCESS Newswire | Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.Lead Asset Positioned for Significant Markets:... ► Artikel lesen | |
| 27.08. | Valion Bio, Inc.: Valion Bio Announces Reverse Stock Split | 611 | ACCESS Newswire | SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock... ► Artikel lesen | |
| 27.08. | Valion Bio announces 1-for-25 reverse stock split | 2 | Investing.com | ||
| 27.08. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.08. | Valion Bio mit Führungswechsel und neuer Finanzierung | 2 | Investing.com Deutsch | ||
| 17.08. | Valion Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08. | Valion Bio, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 13.08. | Valion Bio, Inc.: Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase | 673 | ACCESS Newswire | Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry... ► Artikel lesen |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 63,35 | 0,00 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| HEARTFLOW | 49,440 | -0,04 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 8,235 | +0,06 % | Morning Market Movers: Veea, NFT Limited, WISeSat.Space, Alignment Healthcare See Big Swings | NEW YORK CITY (dpa-AFX) - At 8:15 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CONCENTRA GROUP | 37,430 | -0,03 % | Biotech Stocks At 52-Week Highs - Retension Pharmaceuticals Rises With IPO, Biogen, Concentra Group, Hinge Health, HealthStream | WESTON (dpa-AFX) - The following biotech stocks reached a 52-week high on October 12, 2026, driven by catalysts such as achieving promising clinical data or a public offering.Biogen Inc. (BIIB)Biogen... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,520 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 39,240 | +2,37 % | BERNSTEIN RESEARCH stuft FMC FRESENIUS MEDICAL CARE AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Fresenius Medical Care (FMC) angesichts eines Wechsels an der Konzernspitze auf "Market-Perform" mit einem... ► Artikel lesen | |
| GENEDX | 68,49 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| FRESENIUS | 43,790 | +0,53 % | VW und Autobauer im Fokus: DAX vor dem nächsten Schub? Diese Woche wird für Anleger entscheidend | © Foto: Boris Roessler/dpaDer DAX dürfte freundlich in die neue Woche starten. Auch die europäischen Futures liegen im Plus. Doch Öl, Inflation und die beginnende US-Berichtssaison könnten schnell für... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 40,190 | +0,30 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,680 | 0,00 % | Privia Health Group, Inc.: Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 | ||
| AVEANNA HEALTHCARE | 12,375 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 17,515 | +0,03 % | PROCEPT BioRobotics to Report Third Quarter 2026 Financial Results on November 4th, 2026 | ||
| STARLING ONCOLOGY INSTITUTE | 6,510 | 0,00 % | Needham raises Starling Oncology stock price target on growth outlook | ||
| PROGYNY | 27,830 | -0,04 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| DRAEGERWERK | 102,20 | -12,35 % | Draegerwerk AG & Co. KGaA: Sechsjähriger FDA-Belastungsfaktor beseitigt; US-Monitoring-Geschäft rückt wieder in den Fokus; KAUFEN | Dräger hat ein sechs Jahre währendes regulatorisches Kapitel im US-Patientenmonitoring endlich abgeschlossen. Nach der FDA-Freigabe (Clearance) von Dräger IACS VG8.1 hat die Behörde den 2020 ausgesprochenen... ► Artikel lesen |
Das Unternehmen VALION BIO INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALION BIO INC finden Sie auf Wallstreet Online.